AbbVie, J&J concede a failure for blockbuster Imbruvica in their PhIII shot at pancreatic cancer
Pancreatic cancer has beaten another Phase III effort aimed at improving the prospects of patients fighting the disease.
Just ahead of the 3-day weekend, AbbVie …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.